The incidence and prevalence of metabolic syndrome (MS) and colorectal cancer (CRC) has been rising in developed countries. The association between these two diseases has been widely studied and reported. Less evidence is available about the relationship between MS and CRC precancerous lesions (adenomatous polyps, adenomas). The aim of this paper is to present an overview of our scientific understanding of that topic and its implication in clinical practice. One of the principal goals of current CRC secondary prevention efforts is to detect and remove the precancerous lesions in individuals with an average CRC risk to prevent the development of invasive cancer. MS is not currently considered a high-risk CRC factor and is therefore not included in the guidelines of organized screening programs. However, in light of growing scientific evidence, the approach to patients with MS should be changed. Metabolic risk factors for the development of adenomas and cancers are the same - obesity, impaired glucose tolerance, dyslipidemia, hypertension, cardiovascular diseases and diabetes mellitus type 2. Therefore, the key issue in the near future is the development of a simple scoring system, easy to use in clinical practice, which would identify individuals with high metabolic risk of colorectal neoplasia and would be used for individual CRC secondary prevention strategies. Currently, such scoring systems have been published based on Asian (Asia-Pacific Colorectal Screening Score; APCS) and Polish populations.

Stepan Suchanek Tomas Grega Gabriela Vojtechova Petra Minarikova Nagyija Brogyuk Bohus Bunganic Miroslav Zavoral Department of Internal Medicine 1 Faculty of Medicine Charles University Military University Hospital CZ 169 02 Prague Czech Republic

Zobrazit více v PubMed

O'Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015;16:1–12. PubMed

Cífková R, Skodová Z, Bruthans J, Adámková V, Jozífová M, Galovcová M, Wohlfahrt P, Krajcoviechová A, Poledne R, Stávek P, et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis. 2010;211:676–681. PubMed

Guize L, Pannier B, Thomas F, Bean K, Jégo B, Benetos A. Recent advances in metabolic syndrome and cardiovascular disease. Arch Cardiovasc Dis. 2008;101:577–583. PubMed

Peeters PJ, Bazelier MT, Leufkens HG, de Vries F, De Bruin ML. The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity. Diabetes Care. 2015;38:495–502. PubMed

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. PubMed

Dusek L, Muzik J, Kubasek M, Koptikova J, Zaloudik J, Vyzula R. Epidemiology of malignities in the Czech Republic. Masarykova univerzita online, 2005, cited 2016-03-30. Available from: http://www.svod.cz/

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer Incidence and Mortality Worldwide. GLOBOCAN 2012 v1.0, online 2013, cited 2016-03-30. Available from: http://globocan.iarc.fr/ PubMed

Prorok P, Kramer B, Gohagan J. Screening Theory and Study Design: The Basics. In: Kramer B, Gohagan J, Prorok P. Cancer Screening - Theory and Practise. New York: Marcel Dekker, 1999 In: Kramer B, Gohagan J, Prorok P, editors.

Suchanek S, Majek O, Vojtechova G, Minarikova P, Rotnaglova B, Seifert B, Minarik M, Kozeny P, Dusek L, Zavoral M. Colorectal cancer prevention in the Czech Republic: time trends in performance indicators and current situation after 10 years of screening. Eur J Cancer Prev. 2014;23:18–26. PubMed

Zavoral M, Suchanek S, Majek O, Fric P, Minarikova P, Minarik M, Seifert B, Dusek L. Colorectal cancer screening: 20 years of development and recent progress. World J Gastroenterol. 2014;20:3825–3834. PubMed PMC

Segnan N, Patnick J, von Karssa L. European guidelines for quality assurance in colorectal cancer screening and diagnosis. 1st ed. Luxembourg: Publications Office of the European Union, 2010

Kaminski MF, Polkowski M, Kraszewska E, Rupinski M, Butruk E, Regula J. A score to estimate the likelihood of detecting advanced colorectal neoplasia at colonoscopy. Gut. 2014;63:1112–1119. PubMed PMC

Zhou JR, Blackburn GL, Walker WA. Symposium introduction: metabolic syndrome and the onset of cancer. Am J Clin Nutr. 2007;86:s817–s819. PubMed PMC

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645. PubMed

Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 2010;61:301–316. PubMed

Paz-Filho G, Lim EL, Wong ML, Licinio J. Associations between adipokines and obesity-related cancer. Front Biosci (Landmark Ed) 2011;16:1634–1650. PubMed

Murphy TK, Calle EE, Rodriguez C, Kahn HS, Thun MJ. Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol. 2000;152:847–854. PubMed

Robsahm TE, Aagnes B, Hjartåker A, Langseth H, Bray FI, Larsen IK. Body mass index, physical activity, and colorectal cancer by anatomical subsites: a systematic review and meta-analysis of cohort studies. Eur J Cancer Prev. 2013;22:492–505. PubMed

Ashktorab H, Paydar M, Yazdi S, Namin HH, Sanderson A, Begum R, Semati M, Etaati F, Lee E, Brim H, et al. BMI and the risk of colorectal adenoma in African-Americans. Obesity (Silver Spring) 2014;22:1387–1391. PubMed PMC

Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev. 2007;16:2533–2547. PubMed

Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr. 2007;86:556–565. PubMed

Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev. 2010;11:19–30. PubMed

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333. PubMed

Ritenbaugh C, Stanford JL, Wu L, Shikany JM, Schoen RE, Stefanick ML, Taylor V, Garland C, Frank G, Lane D, et al. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women’s Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2008;17:2609–2618. PubMed PMC

Liu CS, Hsu HS, Li CI, Jan CI, Li TC, Lin WY, Lin T, Chen YC, Lee CC, Lin CC. Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population. BMC Gastroenterol. 2010;10:51. PubMed PMC

Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjønneland A, Halkjaer J, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC) J Natl Cancer Inst. 2006;98:920–931. PubMed

Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Rafaniello C, Panagiotakos DB, Giugliano D. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine. 2013;44:634–647. PubMed

Ozasa K, Ito Y, Suzuki K, Watanabe Y, Kojima M, Suzuki S, Tokudome S, Tamakoshi K, Toyoshima H, Kawado M, et al. Glucose intolerance and colorectal cancer risk in a nested case-control study among Japanese People. J Epidemiol. 2005;15 Suppl 2:S180–S184. PubMed PMC

Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11:385–391. PubMed

Vigneri PG, Tirrò E, Pennisi MS, Massimino M, Stella S, Romano C, Manzella L. The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy. Front Oncol. 2015;5:230. PubMed PMC

Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293:194–202. PubMed

Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol. 2011;106:1911–1921; quiz 1922. PubMed PMC

Krämer HU, Schöttker B, Raum E, Brenner H. Type 2 diabetes mellitus and colorectal cancer: meta-analysis on sex-specific differences. Eur J Cancer. 2012;48:1269–1282. PubMed

Yang W, Chang Y, Huang H, Wang Y, Yu X. Association between Obesity, Serum Lipids, and Colorectal Polyps in Old Chinese People. Gastroenterol Res Pract. 2013;2013:931084. PubMed PMC

Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:412–418. PubMed

Tsushima M, Nomura AM, Lee J, Stemmermann GN. Prospective study of the association of serum triglyceride and glucose with colorectal cancer. Dig Dis Sci. 2005;50:499–505. PubMed

Borena W, Stocks T, Jonsson H, Strohmaier S, Nagel G, Bjørge T, Manjer J, Hallmans G, Selmer R, Almquist M, et al. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control. 2011;22:291–299. PubMed

Ulmer H, Borena W, Rapp K, Klenk J, Strasak A, Diem G, Concin H, Nagel G. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer. 2009;101:1202–1206. PubMed PMC

van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, Jenab M, Pischon T, Jansen EH, Frohlich J, Ayyobi A, Overvad K, Toft-Petersen AP, et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut. 2011;60:1094–1102. PubMed

Siddiqui AA. Metabolic syndrome and its association with colorectal cancer: a review. Am J Med Sci. 2011;341:227–231. PubMed

Kim JH, Lim YJ, Kim YH, Sung IK, Shim SG, Oh SO, Park SS, Yang S, Son HJ, Rhee PL, et al. Is metabolic syndrome a risk factor for colorectal adenoma? Cancer Epidemiol Biomarkers Prev. 2007;16:1543–1546. PubMed

Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006;107:28–36. PubMed

Bowers K, Albanes D, Limburg P, Pietinen P, Taylor PR, Virtamo J, Stolzenberg-Solomon R. A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol. 2006;164:652–664. PubMed

Lin CC, Huang KW, Luo JC, Wang YW, Hou MC, Lin HC, Lee FY, Chan WL. Hypertension is an important predictor of recurrent colorectal adenoma after screening colonoscopy with adenoma polypectomy. J Chin Med Assoc. 2014;77:508–512. PubMed

Watanabe Y, Yamaji Y, Kobayashi Y, Yoshida S, Sugimoto T, Yamada A, Watabe H, Hirata Y, Koike K. Association between colorectal polyps and hypertension treatment. J Dig Dis. 2015;16:649–655. PubMed

Chan AO, Lam KF, Tong T, Siu DC, Jim MH, Hui WM, Lai KC, Yuen MF, Lam SK, Wong BC. Coexistence between colorectal cancer/adenoma and coronary artery disease: results from 1382 patients. Aliment Pharmacol Ther. 2006;24:535–539. PubMed

Yang SY, Kim YS, Chung SJ, Song JH, Choi SY, Park MJ, Yim JY, Lim SH, Kim D, Kim CH, et al. Association between colorectal adenoma and coronary atherosclerosis detected by CT coronary angiography in Korean men; a cross-sectional study. J Gastroenterol Hepatol. 2010;25:1795–1799. PubMed

Chan AO, Jim MH, Lam KF, Morris JS, Siu DC, Tong T, Ng FH, Wong SY, Hui WM, Chan CK, et al. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA. 2007;298:1412–1419. PubMed

Lee JY, Hong SN, Kim JH, Choe WH, Lee SY, Sung IK, Park HS, Shim CS. Risk for coronary heart disease increases risk for colorectal neoplasm. Clin Gastroenterol Hepatol. 2013;11:695–702. PubMed

Basyigit S, Ozkan S, Uzman M, Ertugrul DT, Kefeli A, Aktas B, Yeniova AO, Asilturk Z, Nazligul Y, Simsek H, et al. Should screening for colorectal neoplasm be recommended in patients at high risk for coronary heart disease: a cross-sectional study. Medicine (Baltimore) 2015;94:e793. PubMed PMC

Trabulo D, Ribeiro S, Martins C, Teixeira C, Cardoso C, Mangualde J, Freire R, Gamito É, Alves AL, Augusto F, Oliveira AP, Cremers I. Metabolic syndrome and colorectal neoplasms: An ominous association. World J Gastroenterol. 2015;21:5320–5327. PubMed PMC

Yeoh KG, Ho KY, Chiu HM, Zhu F, Ching JY, Wu DC, Matsuda T, Byeon JS, Lee SK, Goh KL, et al. The Asia-Pacific Colorectal Screening score: a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian subjects. Gut. 2011;60:1236–1241. PubMed

Wang JY, Li ZT, Zhu YM, Wang WC, Ma Y, Liu YL. Utility of the Asia-Pacific colorectal screening scoring system and the presence of metabolic syndrome components in screening for sporadic colorectal cancer. World J Gastroenterol. 2014;20:11394–11399. PubMed PMC

Corte C, Zhang L, Chen J, Westbury S, Shaw J, Yeoh KG, Leong R. Validation of the Asia Pacific Colorectal Screening (APCS) score in a Western population: An alternative screening tool. J Gastroenterol Hepatol. 2016;31:370–375. PubMed

Ruco A, Stock D, Hilsden RJ, McGregor SE, Paszat LF, Saskin R, Rabeneck L. Evaluation of a clinical risk index for advanced colorectal neoplasia among a North American population of screening age. BMC Gastroenterol. 2015;15:162. PubMed PMC

Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003. PubMed

Brenner H, Altenhofen L, Stock C, Hoffmeister M. Expected long-term impact of the German screening colonoscopy programme on colorectal cancer prevention: analyses based on 4,407,971 screening colonoscopies. Eur J Cancer. 2015;51:1346–1353. PubMed

Pathophysiological Characteristics Linking Type 2 Diabetes Mellitus and Colorectal Neoplasia